Dual BET and CBP/p300 Inhibitor in Patients With Targeted Advanced Solid Tumors and Hematological Malignancies

Phase 1 Recruiting 75 enrolled Epigenetix, Inc.

Non-randomizedSingle-groupOpen-labelTreatment

Summary

A Phase 1, first-in-human study of EP31670, a dual BET and CBP/p300 inhibitor in patients with targeted advanced solid tumors and Hematological Malignancies

Timeline

Start: 2022-12-21
Primary completion: 2025-05
Completion: 2025-05

Publications

Eickhoff N, Bergman AM, Zwart W. Homing in on a Moving Target: Androgen Receptor Cistromic Plasticity in Prostate Cancer. Endocrinology. 2022 Oct 11;163(11):bqac153. doi: 10.1210/endocr/bqac153.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	EP31670	Unknown	5 mg	Oral
Subject	EP31670	Unknown	10 mg	Oral
Subject	EP31670	Unknown	20 mg	Oral

Dual BET and CBP/p300 Inhibitor in Patients With Targeted Advanced Solid Tumors and Hematological Malignancies

Summary

Timeline

Publications

Drugs

Indications